Transplant Diagnostics Market Poised to Take Off by 2026

Transplant Diagnostics Market Revenue Growth
Predicted by 2017-2026
Transplant Diagnostics Market, by Product Type (Instrument, Reagents & Kits,
and Software), by Technology (Molecular Assay, and Non-Molecular Assay), by
Application (Tissue Typing, Infectious Disease Testing, Serum-Cross Matching,
and Blood Profiling), by Organ Type (Kidney, Liver, Heart, Lungs, Pancreas, and
Others), by End User (Hospitals & Transplant Centers, Research Laboratories &
Academic Institutes, and Commercial Service Providers) and Region - Global
Trends, and Forecast to 2025
Transplant diagnostics involves assessing compatibility between organ donor and receiver so as to
predict any future organ rejection episodes and have contingencies in place. Number of tests are
performed such as ABO blood group compatibility, tissue typing, cross matching, panel reactive
antibody test, serology screening, and testing for infectious diseases. Increased understanding of the
organ rejection phenomenon has led to identification of robust biomarkers along with development of
robust biomarker identification tests. The Global Transplant Diagnostics Market was valued at US$
544.2 million in 2016 and is expected to witness a robust CAGR of 8.4% over the forecast period
(2017–2025).
Technological advancements in the molecular and non-molecular assays such as PCR, and NGS has
increased the data throughput. However, high cost of transplant diagnostic products, limited medical
reimbursement, and low awareness about organ transplantation in emerging economies such as Middle
East and Asia Pacific is expected to be a factor hindering the transplant diagnostics market growth.
Market Dynamics
Rising prevalence of chronic diseases leading to multiple organ failures; benefits offered by transplant
diagnostics, which can predict organ rejection episodes and help in preparing a contingency plan;
increasing government initiatives for organ donation awareness; and research and development by
leading players to enhance transplant diagnostic products is expected to boost growth of the transplant
diagnostics market over the forecast period. For instance, Natera, Inc. and University of California, San
Francisco (UCSF), announced a research collaboration in 2016, to study DNA markers of Kidney
Transplant Rejection. Furthermore, in 2016, the U.S. government announced plans to invest US$ 200
million to shorten the waiting list of organ transplant patients. These factors are expected to aid in
growth of the market over the forecast period.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/1335
Advancement in technology in diagnostics is expected to drive growth of the transplant
diagnostics market
Advent of new diagnostic tests have improved medical outcomes associated with organ transplants.
Organ rejection rate can be minimized by matching the donor and recipient compatibility before
transplantation. Conventional techniques in transplant diagnostics include analysis of human leukocyte
antigen (HLA). HLA analysis is done in high-throughput laboratories with a limited staff, which is time
consuming. However, presence of molecular assay technologies, such as sequencing techniques and
PCR-based assays have proved to be efficient.
Genetic information can be interpreted on a large scale by using advanced next generation sequencing
(NGS) technologies at an affordable price. For instance, Illumina’s MiSeq system offers highresolution HLA typing and uses next generation sequencing technology, which can be used by any
laboratory. In December 2015, Immucor and Sirona Genomics introduced MIA FORA NGS—a highresolution HLA typing solution—that provides accurate and detailed coverage of 11 HLA genes.
Furthermore, HLA analysis at the DNA level is possible due to technologies such as PCR-RFLP, PCRSSP, PCR-SSO, PCR-SSCP, and PCR-SNP.
Key Companies
Some major players operating in the transplant diagnostics market are Thermo Fisher Scientific, Inc.,
Bio-Rad Laboratories, Inc., Qiagen N.V., F. Hoffman-La Roche Ltd., Immucor, Inc., Becton Dickinson
and Company, bioMérieux S.A., Illumina, Inc., CareDx, Inc., and GenDx.
Government initiatives to promote organ transplantation along with awareness initiatives for the
same is supporting growth of the transplant diagnostics market
Increasing number of transplantation is expected to increase demand for transplant diagnostics, in order
to reduce episodes of organ rejection. Various organizations such as World Health Organization (WHO)
and World Health Assembly have implanted action plans such as WHA57.18 to increase awareness
regarding transplantation. National Health Service (NHS) Blood & Transplant funded a living
transplant initiative in 2016, which was led by the National BAME Transplant Alliance, to increase the
number of living transplants from black, Asian, and minority ethnic (BAME) communities. Moreover,
in 2015, the Health Resources and Services Administration in the U.S. initiated the Organ Donation and
Transplantation Funding program and allocated US$ 24 million for research.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

Transplant diagnostics involves assessing compatibility between organ donor and receiver so as to predict any future organ rejection episodes and have contingencies in place. Number of tests are performed such as ABO blood group compatibility, tissue typing, cross matching, panel reactive antibody test, serology screening, and testing for infectious diseases.

Download Report